spacer
home > pmps > winter 2002 > modified-release oral solid dosage forms - part i: coating and matrix formation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Modified-Release Oral Solid Dosage Forms - Part I: Coating and Matrix Formation

This article provides a comprehensive review of the basics of matrix and coating systems on which new drug delivery companies have based their products. It focuses on the investigation of the underlying technical principles of oral solid dosage forms (tablets and particles) by classifying them as matrix or coating systems. The materials chemistry and processing (formulation and formation methods) of matrix or coating oral solid dosage forms have been investigated. Processing of commercial matrix or coating systems is different.

The conventional processing described provides the basics for what is now all-in-one granulation using fluid beds (top-spray for matrices and bottom or tangential-spray for coatings). Each system's specific parameters (polymer hydration and gel formation for matrices, insolubility for coatings) and common parameters (particle size, shape of all particles, drug per cent, polymer blend solubility, flexibility and compressibility) are discussed. The current trends resulted from these basic technical formation principles.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Emmanuel Dimotakis PhD and Robert A Nash PhD, Department of Chemical
and Pharmaceutical Engineering at the New Jersey Institute of Technology

Dr Emmanuel Dimotakis joined Sun Chemical as an Associate Scientist in 1998 and is currently a Scientist II. His expertise is in product development with emphasis on nanostructure-property relationships and formulation/rheology of polymers for coatings/colorants, nanomaterials and lithography. He has introduced products into the market, published 15 articles, 3 US/WO Patents (others are pending) and 12 government reports to NASA/DOD.

He was formerly with E. Merck and before that with MER Corporation. Dr Dimotakis received his PhD in Chemistry at Michigan State University in 1990 and undertook Postdoctoral work in Materials Science and Engineering at the University of Illinois at Urbana-Champaign.

Dr Robert A Nash is Adjunct Professor of Pharmaceutical Engineering at Stevens Institute of Technology in Hoboken, USA. Before that he taught at NJIT and St John's University.

Dr Nash spent 24 years in the US pharmaceutical industry with Merck, Lederle and the Purdue Frederick Co. in roles varying from Researcher to Manager of Pharmaceutical R&D. Dr Nash is Co-Editor of Pharmaceutical Process Validation published by Marcel Dekker & Co, New York. He is also a Consultant to the US FDA on validation and GMP matters.


spacer
Dr Emmanuel Dimotakis
spacer
spacer
spacer
Dr Robert A Nash
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement